Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Osteoporosis
•
Gluocorticoid Induced Osteoporosis
When considering pharmacologic treatments recommended by the 2022 glucocorticoid induced osteoporosis guidelines, do you use NNT/NNH to select between each treatment option by risk categories (e.g., moderate, high, very high)?
Related Questions
How would you approach treatment of glucocorticoid induced osteoporosis in a patient 10 years post renal transplant, egfr > or =35, on chronic prednisone therapy who has completed 10 years of bisphosphonate therapy and whose DEXA continues to be T-score <~2.5?
Would one year of steroids for JRA during teen years (with subsequently well-controlled autoimmune disease) be sufficient to explain a vertebral T score of -4.4 of a woman in her early 50s without any other risk factors?
Have the results of the ancillary study of the VITAL trial, demonstrating that Vitamin D3 supplementation did not reduce the incident rate of fractures in generally healthy midlife and older adults, changed how you prescribe Vitamin D?
What treatment would you consider for severe osteoporosis in a patient with multiple fractures, AVN of jaw from denosumab, history of stroke and who has completed a PTH analog?
Would you use PTH analog in a patient with severe osteoporosis (T score below - 3.5) who has been found to have idiopathic hypercalciuria with normal labs (PTH, vit D, Ca)?
How would you approach a finding of osteoporosis (Z score -4.5) in a recently postpartum patient who had DEXA sent for long term low-dose glucocorticoid use?
What do you consider as absolute and relative contraindications for the use of romosozumab?
What is your approach to a patient on long-term denosumab who now requires multiple invasive dental procedures?
How do you time Evenity after completion of Forteo?
For a patient with osteopenia or osteoporosis, how long can intravenous zoledronic acid be maintained if there are not adverse events?
